Summary
Single-organ metastasis and a low TN status (especially in combination), limited local metastasis, and active anticancer treatment are prognostic for a longer overall survival in patients with stage IV non–small cell lung cancer, according to a retrospective analysis using the National Cancer Registry in The Netherlands. Overall survival is longer in patients whose disease is staged using 18-fluoro-deoxyglucose positron emission tomography imaging.
- 18-fluoro-deoxyglucose positron emission tomography imaging
- adenocarcinoma
- intrathoracic metastasis
- extrathoracic lymph node metastasis
- stage IV non–small cell lung cancer
- TN status
- oncology trials
- © 2015 SAGE Publications